Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023)

Zentalis Pharmaceuticals (ZNTL) has 2 years of Deferred Taxes data on record, last reported at -$756000.0 in Q2 2023.

  • For Q2 2023, Deferred Taxes fell 1121.62% year-over-year to -$756000.0; the TTM value through Mar 2024 reached -$756000.0, up 4.55%, while the annual FY2023 figure was -$853000.0, 10.92% down from the prior year.
  • Deferred Taxes reached -$756000.0 in Q2 2023 per ZNTL's latest filing, down from -$97000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $74000.0 in Q2 2022 and bottomed at -$769000.0 in Q4 2022.